
Adam M Boruchov MD
Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology
SVP, Chair of Cancer Institute, Nuvance Health Professor of Medicine, University of Connecticut SOM
Join to View Full Profile
21 Elm StNew Milford, CT 06776
Dr. Boruchov is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2000 - 2003
- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1997 - 2000
- State University of New York Downstate Medical Center College of MedicineClass of 1997
Certifications & Licensure
- CT State Medical License 2008 - 2025
- NY State Medical License 1998 - 2010
- American Board of Internal Medicine Hematology
Clinical Trials
Publications & Presentations
PubMed
- Long-term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia.Christine E Ryan, Yue Ren, Svitlana Tyekucheva, Jon E Arnason, Adam M Boruchov
Hemasphere. 2025-01-01 - 21 citationsImmune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.Romanos Sklavenitis-Pistofidis, Michelle P Aranha, Robert A Redd, Joanna Baginska, Nicholas J Haradhvala
Cancer Cell. 2022-11-14 - 19 citationsRomidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohortsNeha Mehta-Shah, Matthew A. Lunning, Alison J. Moskowitz, Adam M. Boruchov, Jia Ruan
American Journal of Hematology. 2021-07-12
Press Mentions
- Yale Researchers Say Customized Cancer Vaccine Shows PromiseMay 20th, 2023
- Study Shows That Immune System Holds Clues to Patients with High-Risk Smoldering Myeloma Likely to Benefit from TreatmentNovember 15th, 2022
- Nuvance Health Appoints Adam Boruchov, MD, System Chair of the Cancer InstituteOctober 26th, 2023
Grant Support
- Targeting Fcrs On Dcs For Ag-Specific ToleranceNational Institute Of Allergy And Infectious Diseases2005–2008
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: